In Cross-Appeal Of Patent Dispute Over Biosimilars, Federal Circuit Panel Affirms
Mealey's (December 17, 2019, 2:25 PM EST) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on Dec. 16 upheld in all respects a Delaware jury’s determination that a patent covering the anemia drug “Epogen” is...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login